Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week

Latest news

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Intraday Update
  • Markets
  • Movers
  • News
  • Penny Stocks
  • Small Cap
  • Trading Ideas

Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin
Today, 1:20 PM
Gainers Amesite Inc. (NASDAQ: AMST) shares jumped 123% to $0.6284 after the company announced GPT-3 powered functionality to its AI toolkit for customers and users.

AMST

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks

IMV Stock Falls After Interim Data From Lead Candidate In Blood Cancer Subtype

By Vandana Singh
Today, 1:20 PM
IMV Inc (NASDAQ:IMV) announced preliminary data from the VITALIZE Phase 2B trial evaluating its lead DPX product, maveropepimut-S (MVP-S), in combination…

IMV

Read More
1 minute read
  • Dividends
  • Earnings
  • News

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,100 Today

By Benzinga Insights
Today, 1:20 PM
Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 6.82% on an annualized…

MRK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News
  • Penny Stocks

Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce

By Vandana Singh
Today, 1:20 PM
Aligos Therapeutics Inc (NASDAQ:ALGS) announced a portfolio reprioritization, with priorities focused on the rapid advancement of its clinical NASH (ALG-055009)…

ALGS

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Price Target
  • Reiteration
  • Small Cap
  • Trading Ideas

Analyst Reiterates This Alzheimer’s Candidate As Top Idea For 2023

By Vandana Singh
Today, 1:20 PM
Mizuho raised the price target on BioXcel Therapeutics Inc (NASDAQ:BTAI) from $24 to $38, with a Buy rating. Since the analyst’s previous…

BTAI

Read More
1 minute read
  • Dividends
  • Earnings
  • News

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,000 Today

By Benzinga Insights
Today, 1:20 PM
Merck & Co (NYSE:MRK) has outperformed the market over the past 5 years by 6.07% on an annualized…

MRK

Read More
1 minute read
  • Analyst Color
  • Analyst Ratings
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Price Target
  • Trading Ideas
  • Upgrades

Analyst Upgrades Personalis; Says Biopharma Is Strong, Cash Burn Is Down

By Vandana Singh
Today, 1:20 PM
Needham has upgraded Personalis Inc (NASDAQ:PSNL) to Buy from Hold with a price target of $8. The analyst writes that Personalis’s cash…

MRK

Read More
1 minute read
  • Biotech
  • Contracts
  • General
  • Health Care
  • Large Cap
  • Movers
  • News
  • Penny Stocks

Why Personalis Shares Are Trading Higher Today

By Vandana Singh
Today, 1:20 PM
Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming…

MRK

Read More
1 minute read
  • Analyst Ratings
  • News
  • Price Target

Morgan Stanley Maintains Equal-Weight on Merck & Co, Lowers Price Target to $99

By Benzinga Newsdesk
Today, 1:20 PM
Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Equal-Weight and lowers the price target from $100 to $99.

MRK

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • News

Merck’s Keytruda (Pembrolizumab) Plus Chemotherapy Improves Progression-Free Survival Versus Standard Chemotherapy Alone As First-line Therapy For Advanced Or Recurrent Endometrial Carcinoma, Meeting Primary Endpoint In Phase 3 Study

By Benzinga Newsdesk
Today, 1:20 PM
The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies; no new safety signals were identified.

MRK

Posts navigation

Previous 1 2 3 4 … 66 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service